This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Haushofer, A. Articles by Fischer, M. Search for Related Content PubMed PubMed Citation Articles by Haushofer, A. Articles by Fischer, M. Social Bookmarking                         What's this?

Quality Assurance of High-Dose IV Heparin Treatment Exemplified by Patients Implanted with Coronary Palmaz-Schatz Stents

Central Laboratory, Unit for Anticoagulant Control and Thrombosis Research

Walter Michael Halbmayer

Central Laboratory, Unit for Anticoagulant Control and Thrombosis Research

Herbert Prachar

Medical Department IV-Cardiology Krankenhaus der Stadt Wien Lainz, Vienna, Austria

Michael Fischer

Central Laboratory, Unit for Anticoagulant Control and Thrombosis Research

The need to standardize treatment with high-dose IV standard heparin by using activated partial thromboplastin time (APTT) reagents tested for their heparin sensitivity and by establishing a standard treatment schedule led to the development of the "Lainz concept" of heparin management. The determination of heparin sensitivity of the 2 APTT reagents used (APTT Micronized Silica and APTT Actin FSL), their good agreement (r=.9977; P=.000), and their therapeutic APTT ratio of 1.5-2.5 fold of baseline APTT (therapeutic range, forty-five to seventy-five seconds) equivalent to 0.3-0.7 antifactor Xa units are presented.

The "Lainz concept" was tested in 29 patients receiving high-dose heparin after coronary artery stenting. A mean dose of 1,273 U of standard heparin/hour (15.7 U/kg body weight/hour) was shown to produce APTTs in the therapeutic range. From the introduction of the "Lainz concept" 81% of the APTTs were kept within the therapeutic range by using a defined heparin-monitoring schedule based on a guideline protocol for controlling heparin treatment. Only 19% of the APTTs were below the therapeutic range. Factors underlying subtherapeutic APTTs are discussed. The reduction in the rate of subtherapeutic APTTs to less than 3% seen after the introduction of the "Lainz concept" constitutes an important contribution toward quality assurance in high-dose heparin treatment.

Angiology, Vol. 46, No. 4, 305-311 (1995)
DOI: 10.1177/000331979504600404


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?